Farletuzumab (MORAb-003) is a humanized monoclonal antibodyStatement On A Nonproprietary Name Adopted By The Usan Council - Farletuzumab, American Medical Association. of IgG1/κ which is being investigated for the treatment of ovarian cancer.
This drug was developed by Morphotek, Inc.
It is targeted at folate receptor alpha (FRα) which is overexpressed in some cancers such as epithelial ovarian cancer (EOC) and non-small-cell lung carcinoma.
Mechanism of action Farletuzumab uses the following mechanisms of action:
Antibody-dependent cellular cytotoxicity Complement-dependent cytotoxicity Inhibition of interaction between FRα and Lyn kinase Induces cell death associated with autophagy
Adverse effects Common adverse effects include hypersensitivity reactions, fever, chills, headache, fatigue, and diarrhea.
References